
News Releases

News Releases

2010

Aug 3, 2010	Santen Announces Financial Result for the First Quarter ended June 30, 2010
Jul 6, 2010	Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Jun 23, 2010	Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Jun 11, 2010	Banyu and Santen Launch COSOPT® Combination Ophthalmic Solution: Glaucoma and Ocular Hypertension Drug
May 11, 2010	Renewal of the Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
May 11, 2010	Notice of the Change of Representative Director and the Nominations for the Members of the Board of Directors
May 11, 2010	Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers
May 11, 2010	Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors
May 11, 2010	Santen Announces Financial Results for the Year ended March 31, 2009
May 6, 2010	Santen Launches Glaucoma and Ocular Hypertension Treatment TAFLOTAN® in Korea
May 3, 2010	Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen for Development of Ophthalmic Treatments
Apr 16, 2010	MHLW Grants Approval for COSOPT Combination Ophthalmic Solution
Apr 16, 2010	Santen Announces Approval of DIQUAS for Dry Eye Treatment in Japan
Mar 10, 2010	Change of management positions at Santen Inc.
Mar 10, 2010	Notice of the appointment of Corporate Officers
Mar 2, 2010	Banyu and Santen Announce Co-Promotion Agreement for Combination Ophthalmic Solution, Treatment for Glaucoma and Ocular Hypertension
Mar 2, 2010	Santen Files Manufacturing/Marketing Approval of its Broad Spectrum Anti-Infective Ophthalmic Solution DE-108 (Generic name: Levofloxacin, high concentration)
Feb 2, 2010	Santen Announces Financial Result for the Third Quarter ended December 31, 2009


	Download Adobe® Reader® to view PDF files.

News Releases

2010